Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion type Assertion NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_head.
- NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion description "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_provenance.
- NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion evidence source_evidence_literature NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_provenance.
- NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion SIO_000772 22781593 NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_provenance.
- NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion wasDerivedFrom befree-20140225 NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_provenance.
- NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion wasGeneratedBy ECO_0000203 NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_provenance.